Strides Pharma Science Ltd is Rated Hold

Rating Overview and Context

On 06 Apr 2026, MarketsMOJO revised its assessment of Strides Pharma Science Ltd, moving the rating from 'Sell' to 'Hold'. This change was accompanied by a significant improvement in the Mojo Score, which rose by 23 points from 40 to 63. The 'Hold' rating indicates a neutral stance, suggesting that while the stock may not currently offer strong upside potential, it is not expected to underperform significantly either. Investors should consider this rating as a signal to maintain existing positions without aggressive buying or selling.

Here’s How the Stock Looks Today

As of 21 May 2026, Strides Pharma Science Ltd exhibits a mixed but cautiously optimistic profile across key investment parameters. The company operates within the Pharmaceuticals & Biotechnology sector and is classified as a small-cap stock. Its current market dynamics and financial health provide a nuanced picture for investors.

Quality Assessment

The quality grade for Strides Pharma is below average, reflecting some challenges in its long-term fundamental strength. The company’s average Return on Capital Employed (ROCE) stands at 8.83%, which is modest and indicates limited efficiency in generating returns from its capital base. Over the past five years, net sales have grown at an annual rate of 7.94%, while operating profit has increased by 11.02% annually. These growth rates, while positive, are relatively subdued compared to sector peers. Additionally, the company’s debt servicing capacity is constrained, with a Debt to EBITDA ratio of 1.90 times, signalling moderate leverage risk.

Valuation Perspective

Valuation metrics currently favour Strides Pharma Science Ltd, earning it an attractive valuation grade. The stock trades at an Enterprise Value to Capital Employed ratio of 2.6, which is below the average historical valuations of its peers, suggesting it is reasonably priced or undervalued. Despite this, investors should note that while the stock has delivered a robust 64.38% return over the past year, the company’s profits have declined by 14.9% during the same period. This divergence between price appreciation and profit contraction warrants careful consideration.

Financial Trend and Recent Performance

The financial trend for Strides Pharma is very positive, supported by strong recent quarterly results. The company reported a 54.96% growth in net profit in the March 2026 quarter, marking the eleventh consecutive quarter of positive results. Operating profit to interest coverage ratio reached a high of 5.77 times, indicating solid earnings relative to interest expenses. The half-year ROCE improved to 17.96%, and the debt-equity ratio decreased to a low of 0.57 times, reflecting a healthier balance sheet. These factors contribute to a favourable financial outlook despite some underlying quality concerns.

Technical Outlook

Technically, the stock is rated bullish, supported by strong momentum and positive price action. Over the last month, Strides Pharma has gained 14.79%, and over three months, it has surged 31.94%. Year-to-date returns stand at 26.92%, with a one-year return of 64.38%. The stock’s recent day change was a modest +0.28%, indicating steady investor interest. This technical strength suggests that market sentiment remains supportive, which may help sustain the stock’s current valuation levels.

Risks and Considerations

Investors should be mindful of certain risks associated with Strides Pharma Science Ltd. Notably, 27.27% of promoter shares are pledged, which can exert downward pressure on the stock price during market downturns. The company’s weak long-term fundamental strength and moderate leverage also pose challenges. While recent financial trends are encouraging, the below-average quality grade and profit decline over the past year highlight areas requiring close monitoring.

What the Hold Rating Means for Investors

The 'Hold' rating assigned to Strides Pharma Science Ltd by MarketsMOJO suggests a balanced outlook. Investors holding the stock may consider maintaining their positions, as the company demonstrates solid financial trends and attractive valuation, but also faces quality and leverage concerns. The rating implies limited immediate upside potential but also reduced downside risk compared to a 'Sell' rating. For new investors, a cautious approach is advisable, with attention to evolving fundamentals and market conditions.

Summary of Key Metrics as of 21 May 2026

To summarise, the stock’s key performance indicators as of today include:

• Mojo Score: 63.0 (Hold grade)
• Return on Capital Employed (ROCE): 8.83% average; 17.96% half-year high
• Net Sales growth (5 years CAGR): 7.94%
• Operating Profit growth (5 years CAGR): 11.02%
• Debt to EBITDA ratio: 1.90 times
• Debt-Equity ratio (half-year): 0.57 times
• Stock returns: 1Y +64.38%, YTD +26.92%, 3M +31.94%
• Promoter pledged shares: 27.27%

These figures highlight a company with improving financial health and strong market performance, tempered by some structural risks and moderate fundamental quality.

Outlook

Looking ahead, Strides Pharma Science Ltd’s prospects will depend on its ability to sustain profit growth, manage leverage prudently, and capitalise on its attractive valuation. The bullish technical indicators provide a positive backdrop, but investors should remain vigilant about the company’s long-term fundamental challenges and promoter share pledging. The 'Hold' rating reflects this balanced view, encouraging investors to monitor developments closely while maintaining a measured stance.

Conclusion

In conclusion, Strides Pharma Science Ltd’s current 'Hold' rating by MarketsMOJO, updated on 06 Apr 2026, is supported by a combination of attractive valuation, positive financial trends, and bullish technicals, offset by below-average quality and leverage concerns. As of 21 May 2026, the stock presents a cautious opportunity for investors seeking exposure to the pharmaceuticals sector with moderate risk tolerance. Maintaining awareness of evolving fundamentals and market conditions will be key to making informed investment decisions.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today